PHVS logo

PHARVARIS NV

PHVSNASDAQ
๐Ÿ† #1704 by market capEarnings Apr 5 ยท PostUS Equity
$31.31โ–ผ $0.32 (โˆ’1.01%)
Market closed ยท at close
๐Ÿ””
Track PHVS
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 1.0%
7dโ–ผ 6.2%
14dโ–ผ 8.8%
30dโ–ผ 0.4%
ytdโ–ฒ 12.8%
1yโ–ฒ 26.5%
๐ŸฆMarket Cap
$2.20B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$30.96 โ€“ $31.62
52-Week Range
โ€”
Volume (shares)
16,524
Avg Volume (shares)
โ€”
Shares Outstanding
70.2M
Next Earnings
2027-04-05

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
โ€”
Dividend Yield
โ€”
PHVS logo

PHARVARIS NV

PHVS
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About PHARVARIS NV

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
21 analysts
Strong Buy10
Buy10
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.